Vamotinib

N/A

Report date: 2024/11/09 20:00:08
NME

Base Information

Drug NameVamotinib
Drug Alias NamePF-114 mesylatePF-114
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFusion Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFusion Pharma Llc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A